Source:http://linkedlifedata.com/resource/pubmed/id/19194465
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2009-6-10
|
| pubmed:abstractText |
The hematopoietic cell transplantation specific comorbidity index (HCT-CI) has been developed to identify patients at high risk of mortality after an allograft. Reduced-intensity/non-myeloablative regimens have decreased the non-relapse mortality (NRM) in elderly and/or heavily pretreated patients. We performed a retrospective study to assess whether HCT-CI may predict clinical outcomes in a cohort of 203 patients with non-Hodgkin's (NHL; n=108), Hodgkin's lymphomas (HL; n=26), and multiple myeloma (MM; n=69), who were transplanted from a human leucocyte antigen (HLA)-matched sibling (n=121) or an unrelated donor (n=82) after a reduced-intensity regimen (n=154) or a low-dose total body irradiation-based non-myeloblative regimen (n=49). Cumulative incidence of NRM was 5, 16 and 20% at 1 year and 6, 24 and 27% at 2 years, for patients with an HCT-CI of 0, 1-2 and > or =3, respectively. By multivariate analysis, HCT-CI significantly predicted NRM (hazard ratio (HR)=1.6, P=0.03), overall survival (OS; HR=1.62, P<0.001) and progression-free survival (PFS; HR=1.43, P=0.002). Moreover, the Karnofsky performance status was also significantly associated with OS and NRM (HR=1.62, P<0.001 and HR=2.12, P=0.04, respectively). Conditioning type did not affect outcome after stratifying patients by HCT-CI. In the light of our study, all future prospective trials of the Gruppo Italiano Trapianti di Midollo (GITMO) will include the HCT-CI to stratify patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1476-5551
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
23
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1131-8
|
| pubmed:meshHeading |
pubmed-meshheading:19194465-Adolescent,
pubmed-meshheading:19194465-Adult,
pubmed-meshheading:19194465-Aged,
pubmed-meshheading:19194465-Comorbidity,
pubmed-meshheading:19194465-HLA Antigens,
pubmed-meshheading:19194465-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:19194465-Humans,
pubmed-meshheading:19194465-Karnofsky Performance Status,
pubmed-meshheading:19194465-Lymphoma,
pubmed-meshheading:19194465-Middle Aged,
pubmed-meshheading:19194465-Multiple Myeloma,
pubmed-meshheading:19194465-Multivariate Analysis,
pubmed-meshheading:19194465-Predictive Value of Tests,
pubmed-meshheading:19194465-Prognosis,
pubmed-meshheading:19194465-Retrospective Studies,
pubmed-meshheading:19194465-Survival Analysis,
pubmed-meshheading:19194465-Transplantation, Homologous,
pubmed-meshheading:19194465-Transplantation Conditioning,
pubmed-meshheading:19194465-Treatment Outcome,
pubmed-meshheading:19194465-Young Adult
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
|
| pubmed:affiliation |
Hematology Department, IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy. lucia.farina@istitutotumori.mi.it
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|